Assembly Biosciences, Inc. (ASMB) |
|
1.3 0 (0%)
|
12-06 10:23 |
|
Open: |
1.29 |
Pre. Close: |
1.3 |
|
High:
|
1.3 |
Low:
|
1.29 |
|
Volume:
|
4,931 |
Market Cap:
|
63(M) |
|
|
|
Technical analysis |
as of: 2022-12-06 10:16:19 AM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.76 One year: 1.98 |
| Support: |
Support1: 1.2 Support2: 0.99 |
| Resistance: |
Resistance1: 1.5 Resistance2: 1.7 |
| Pivot: |
1.33  |
| Moving Average: |
MA(5): 1.3 MA(20): 1.34
MA(100): 1.77 MA(250): 1.85 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 20.8 %D(3): 23.6 |
| RSI: |
RSI(14): 36.8 |
| 52-week: |
High: 2.45 Low: 1.2 |
| Average Vol(K): |
3-Month: 218 (K) 10-Days: 199 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ASMB ] has closed above bottom band by 21.1%. Bollinger Bands are 47.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.34 - 1.35 |
1.35 - 1.35 |
|
Low:
|
1.25 - 1.25 |
1.25 - 1.26 |
|
Close:
|
1.29 - 1.3 |
1.3 - 1.31 |
|
Company Description |
|
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. |
Headline News |
Tue, 22 Nov 2022
Nintendo goes after SteamGridDB, likely for people doing emulation on Steam Deck - GamingOnLinux
Thu, 17 Nov 2022
IOTA to Release Smart Contract Network ‘Assembly’ And Distribute ASMB Token - newsbtc.com
Wed, 09 Nov 2022
We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate - Simply Wall St
Wed, 09 Nov 2022
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB) - Nasdaq
Tue, 08 Nov 2022
Assembly Biosciences Earnings Miss, Revenue In line In Q3 By Investing.com - Investing.com
Tue, 08 Nov 2022
Assembly Biosciences: Q3 Earnings Snapshot - Houston Chronicle
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
49 (M) |
| Shares Float |
45 (M) |
|
% Held by Insiders
|
1.5 (%) |
|
% Held by Institutions
|
34.5 (%) |
|
Shares Short
|
1,410 (K) |
|
Shares Short P.Month
|
1,400 (K) |
Stock Financials |
|
EPS
|
-2.77 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.1 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-32.5 |
|
Return on Equity (ttm)
|
-80.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.11 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.96 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-85 (M) |
|
Levered Free Cash Flow
|
-52 (M) |
Stock Valuations |
|
PE Ratio
|
-0.47 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.61 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.75 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
